The avan?O research consortium: a mozambique/brazil/texas alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV

Active Cooperative Agreement Awarded Last action

Award ID
U54CA277843
Recipient
Awarding agency
Obligated
$2,522,831

Award facts

Assistance listing
93.397 Cancer Centers Support Grants
Completion date 65% complete
Funding agency
Fogarty International Center National Institutes of Health, Department of Health and Human Services
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The overall vision of the avanço research consortium is to establish sustainable infrastructure to develop research programs focused on HIV-associated malignancies in brazil and mozambique. The research theme chosen for this U54 HIV-associated malignancy research center (HAMRC) is to develop novel, low-cost and technologically feasible approaches for cervical cancer screening, diagnosis, and treatment in women living with HIV (WLWH) in low- and middle-income countries (LMICS). This HAMRC will be a collaboration between institutions in the US, mozambique and brazil and includes investigators with expertise in HIV/aids, cervical cancer, bioengineering, pathology, epidemiology and behavioral science. The investigators have several ongoing scientific and clinical collaborations which include projects across all three countries. Our proposal addresses the NIH priority: to address HIV-associated comorbidities, coinfections and complications, which includes malignancies as a category. HIV infection is a known risk factor for cervical cancer, with WLWH having an approximate 6-fold increased risk of developing cervical cancer. The overall goals of the avanço research consortium include: 1) establish sustainable research infrastructure to perform multi-institutional research studies related to HIV-associated malignancies across institutions in the US, brazil and mozambique. We will build a comprehensive research program focused on identifying novel, low-cost and technologically feasible approaches for the prevention, diagnosis, and treatment of cervical cancer in WLWH in LMICS. 2) conduct two research projects that advance the development of promising low-cost technologies focused on the diagnoses of high-grade cervical dysplasia and invasive cervical cancer among WLWH. 3) facilitate and enhance the professional development of junior investigators to conduct HIV- associated malignancy research in mozambique and brazil. Through our developmental core and shared resource core, we will build research capacity and collaboration through formal research training courses, pilot project funding, and implementation of a project echo® program for research capacity building focused on mentoring and supporting early-career investigators.

Transactions

Action Obligated Date
Amendment $0
Amendment $120,096
Amendment $120,096
Amendment $45,360
Amendment $45,360
Amendment $246,592
Amendment $246,592
Amendment $627,289
Amendment $20,000
Amendment $20,000
Amendment $77,500
Amendment $933,946
Original award $20,000
Show all 13

Subawards

Subrecipient Amount Awarded
William Marsh Rice University The Rice team will maintain the imaging systems used for both Project 1 & 2 throughout the course of the studies. $395,192
Universidade Eduardo Mondlane The AVANÇO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical… $246,592
Baylor College Of Medicine For this application, Drs. Daniel Rosen and Jane Montealegre will assist with Research Project 2 which is to determine the barriers to timely diagnoses after… $44,899
Instituto De Fisica De SAO Carlos Dr. Vanderlei S. Bagnato and his team will 1) work with the Rice University team to develop the automated imaging analysis algorithms for the multi-modal… $45,360
William Marsh Rice University RFA CA-22-011: U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional) Title: The AVANÇO… $395,192
Instituto De Fisica De SAO Carlos Dr. Vanderlei S. Bagnato and his team will 1) work with the Rice University team to develop the automated imaging analysis algorithms for the multi-modal… $141,480
Universidade Eduardo Mondlane UEM will be responsible for the following for this proposal: Conducting two Research Projects that advance the development of promising low cost technologies… $587,997
William Marsh Rice University Dr. Rebecca Richards-Kortum, a professor of bioengineering at Rice University, has extensive experience developing optical imaging systems for early detection… $1,496,519
Baylor College Of Medicine For this application, Drs. Daniel Rosen and Jane Montealegre will assist with Research Project 2 which is to determine the barriers to timely diagnoses after… $146,147

Quick answers

Who received award U54CA277843?

U54CA277843 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on August 1, 2023.

How much is award U54CA277843 worth?

$2,522,831 has been obligated on U54CA277843.

Which agency awarded U54CA277843?

National Cancer Institute (National Institutes of Health) awarded U54CA277843, with funding from Fogarty International Center (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login